338
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Extended follow-up with the Bruton’s tyrosine kinase inhibitor ibrutinib in previously treated Waldenström’s macroglobulinemia

, , &
Pages 1502-1505 | Received 31 Aug 2016, Accepted 06 Oct 2016, Published online: 26 Oct 2016
 

Acknowledgements

The Phase 1 study was supported by Pharmacyclics, LLC, an AbbVie Company. Medical writing support for this manuscript was provided by Swati Ghatpande, PhD, and funded by Pharmacyclics, LLC, an AbbVie Company.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http://dx.doi.org/10.1080/10428194.2016.1247957.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.